Free Trial
NASDAQ:EPRX

Eupraxia Pharmaceuticals 4/1/2024 Earnings Report

Eupraxia Pharmaceuticals logo
$5.36 -0.06 (-1.09%)
As of 08/7/2025 03:16 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eupraxia Pharmaceuticals EPS Results

Actual EPS
-$0.17
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Eupraxia Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eupraxia Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Eupraxia Pharmaceuticals Earnings Headlines

Analysts Set Expectations for EPRX FY2025 Earnings
Critical AI announcement set to ignite AI 2.0
While the market chops sideways and headlines dominate the news cycle, a small group of traders is quietly taking advantage of a reliable volatility pattern. A veteran trader just revealed how his strategy cuts through the noise—using fast trades, clear rules, and no overnight risk.
See More Eupraxia Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

View Eupraxia Pharmaceuticals Profile

More Earnings Resources from MarketBeat